ReviewClinical journal of the American Society of Nephrology : CJASN2014
Gene-gene and gene-environment interactions in apolipoprotein L1 gene-associated nephropathy.
Review in Clinical journal of the American Society of Nephrology : CJASN, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03832166 (A Prospective, Randomized Two Group Study to Evaluate the Feasibility and Initial Efficacy of a Community-engaged Screening, Identification, and F&V Intervention to Improve F&V Intake and CKD Outcomes in 140 AA Adults), which is not on this map. Cited by 65 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Prospective, Randomized Two Group Study to Evaluate the Feasibility and Initial Efficacy of a Community-engaged Screening, Identification, and F&V Intervention to Improve F&V Intake and CKD Outcomes in 140 AA Adults
Who cites it
65 citing papers in PubMed, 4 syntheses or guidelines pooled it, 107 citations in OpenAlex.
- Apolipoprotein L1 risk genotypes and odds of lupus nephritis-associated kidney failure in systemic lupus erythematosus: a systematic review and meta-analysis.Frontiers in medicine · 2026Pooled it
- Apolipoprotein L1 gene variants and kidney disease in patients with HIV: a systematic review and meta-analysis.Journal of nephrology · 2023Pooled it
- Genome-wide association study for time to failure of kidney transplants from African American deceased donors.Clinical transplantation · 2020Pooled it
- Genome-wide association studies suggest that APOL1-environment interactions more likely trigger kidney disease in African Americans with nondiabetic nephropathy than strong APOL1-second gene interactions.Kidney international · 2018Pooled it
- Examination of Potential Modifiers of the Association of APOL1 Alleles with CKD Progression.Clinical journal of the American Society of Nephrology : CJASN · 2015Trial
- APOL1 kidney disease: a critical narrative review of molecular mechanisms, clinical heterogeneity, and the emerging therapeutic landscape.International urology and nephrology · 2026Review
- When Cure Meets Susceptibility: APOL1 -Associated Kidney Injury After Gene Therapy for Sickle Cell Disease.American journal of hematology · 2026Article
- Evaluation for genetic disease in kidney transplant candidates: A practice resource.American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons · 2025Review
- Article
- Kidney transplantation between identical twins with APOL1 homozygote risk alleles - a case report.Frontiers in nephrology · 2025Article
- Interferon-γ induces combined pyroptotic angiopathy and APOL1 expression in human kidney disease.Cell reports · 2024Article
- APOL1 Kidney Risk Variants and Long-Term Kidney Function in Healthy Middle-Aged Black Individuals: The Atherosclerosis Risk in Communities (ARIC) Study.Kidney medicine · 2024Article
- The changing landscape of HIV-associated kidney disease.Nature reviews. Nephrology · 2024Review
- Dietary Patterns, Apolipoprotein L1 Risk Genotypes, and CKD Outcomes Among Black Adults in the Reasons for Geographic and Racial Differences in Stroke (REGARDS) Cohort Study.Kidney medicine · 2023Article
- Association between familial aggregation of chronic kidney disease and its incidence and progression.Scientific reports · 2023Article
- The evolving story of apolipoprotein L1 nephropathy: the end of the beginning.Nature reviews. Nephrology · 2022Review
- Apoprotein L1 risk variants and kidney transplantation: a protocol for systematic review and meta-analysis.The Pan African medical journal · 2022Article
- Air, Land, and Sea: Gene-Environment Interaction in Chronic Disease.The American journal of medicine · 2021Review
- Spatial rank-based multifactor dimensionality reduction to detect gene-gene interactions for multivariate phenotypes.BMC bioinformatics · 2021Article
- Apheresis in Adult With Refractory Idiopathic Nephrotic Syndrome on Native Kidneys.Kidney international reports · 2021Article
5 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 2 countries.
Funding
Abstract
Molecular genetics have revolutionized the understanding of susceptibility to the broad spectrum of kidney diseases with light microscopic appearance of FSGS, particularly in populations with recent African ancestry. These disorders include idiopathic FSGS, HIV-associated nephropathy, severe lupus nephritis, sickle cell nephropathy, and the primary kidney disorder focal global glomerulosclerosis, which had historically been ascribed to systemic hypertension. FSGS was once thought to include a multitude of unrelated disorders with similar histologic appearance. However, variation in the apolipoprotein L1 gene locus is now known to account for the vast majority of such cases in African Americans as well as nearly all the excess risk for FSGS and related forms of progressive nondiabetic nephropathy in populations with recent African ancestry, relative to European ancestry. Inheriting two coding apolipoprotein L1 gene nephropathy risk variants is necessary for susceptibility to CKD; however, these variants alone are insufficient to produce disease. This work reviews the evidence supporting second hits or modifying factors that affect risk for apolipoprotein L1 gene-associated nephropathy and produce the protean manifestations of this common and complex syndrome. Targeting modifiable second factors will lead to preventive therapies for slowing progression of nondiabetic nephropathy in many patients possessing two apolipoprotein L1 gene risk variants. This model of genetic risk coupled with modifiable second hits will serve as a paradigm applicable to patients with CKD of various etiologies as well as a host of other complex disorders.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.